Kidney Transplant Access Gap: What Black Patients Should Ask

If your kidneys are failing, a transplant gives you more years and a better life than dialysis for most people who qualify. That is the headline. The problem is access. Black patients reach the transplant waitlist later, spend more time on dialysis first, and almost never receive a kidney from a living donor. One driver was fixable and is now being fixed: a blood-test formula that made Black patients' kidneys look healthier than they were, which delayed referral and cost real waitlist time. You can ask to get that time back.

Dialysis keeps you alive. A transplant lets you live longer and feel better. A systematic review and meta-analysis of waitlisted patients found that people who received a transplant had markedly lower death rates than those who stayed on the list on dialysis, with most studies reporting a long-term survival benefit. Time on dialysis is itself a risk: the longer you wait, the worse transplant outcomes tend to be. That is the case for getting referred early rather than waiting until you are sick enough that a transplant is harder.

Kidney failure lands hard in Black communities. Black Americans are about 30% of everyone in the United States living with kidney failure while making up 13% of the population, and nearly one in three people on the kidney transplant waitlist is Black. Roughly one in five Black adults has chronic kidney disease. These are not small numbers, and they make the access gap a problem worth fighting over.

For years, the standard way to estimate kidney function, called eGFR, included a race coefficient. When a lab knew or assumed a patient was Black, it adjusted the number upward, reporting kidney function as better than it was. A higher eGFR meant a patient looked further from kidney failure, which delayed the referral to a transplant center and delayed the moment they could start banking time on the waitlist.

That delay was measurable. A 2021 analysis in the Journal of the American Society of Nephrology found that the creatinine-based race adjustment left Black patients with about a 32% shorter window to accrue waitlist time before reaching kidney failure. Waitlist time is currency in transplant: candidates with more accrued time move up the list. Shaving a third off that window pushed Black candidates down a list they should have been climbing.

The kidney community acted. In 2021 the National Kidney Foundation and the American Society of Nephrology task force recommended a new eGFR equation that does not use race, and U.S. labs adopted it. If you have kidney disease and you were tested before 2022, your old eGFR may have used the race-adjusted formula. This connects directly to APOL1-related kidney disease, a genetic driver of faster kidney decline in many people of West African ancestry.

This is the most important action item in this article. In 2023, the Organ Procurement and Transplantation Network began requiring transplant programs to review their waitlists and credit Black kidney candidates the waiting time they lost to the old race-inclusive calculation. Eligible candidates can have their waiting time backdated to when a race-neutral eGFR would have qualified them, which can move them up the list for a deceased-donor kidney.

Programs were directed to complete this review, but the system is not perfect and cases get missed. If you are Black and you were on a kidney waitlist or in evaluation before mid-2022, ask your transplant center directly: was my waiting time reviewed for the eGFR modification, and was my date adjusted? Put the question in writing through your patient portal so there is a record. Back-credited months can be the difference between getting an offer and waiting another year.

A kidney from a living donor is the best version of a transplant. It usually works immediately, lasts longer than a deceased-donor kidney, and can happen before you ever start dialysis. Black patients are the least likely to get one. In a JAMA study tracking two decades of data, only 2.9% of Black waitlisted patients received a living-donor kidney within two years of joining the list in 2014, down from 3.4% in 1995. The trend went the wrong way while the science said living donation should be expanding.

The barriers are practical, not biological. Living donor evaluation costs the donor time and travel, and Black candidates are less likely to have a friend or relative who can absorb that cost or who clears the medical screen. When a willing donor is not a match, paired kidney exchange swaps donors across pairs so two incompatible matches become two compatible transplants. Ask your transplant center about paired exchange and about programs that cover donor expenses. These tools widen the pool of people who can donate to you.

Two variants in a gene called APOL1, common in people of West African ancestry, raise the risk of kidney disease. About 13% of Black Americans carry two high-risk copies and roughly 30% carry one. These variants help explain why kidney disease can progress faster, and they matter on both sides of a transplant. A federally funded study network called APOLLO is tracking how APOL1 genotype in donors and recipients affects how long a transplanted kidney lasts. The practical takeaway: APOL1 testing is increasingly part of evaluating a kidney from a Black living donor, and it is a fair question to raise with your transplant team. Carrying a risk variant does not automatically rule anyone out, and the research is still defining exactly how the genotype should guide decisions.

Start with a nephrologist who will refer you early. Seeing a kidney specialist months before dialysis, not weeks, is tied to higher rates of getting waitlisted and transplanted. Bring three asks to the visit: refer me for a transplant evaluation now, confirm my current eGFR uses the race-neutral formula, and check whether I qualify for back-credited waiting time. Then ask the transplant center about living donation and paired exchange. If you want a clinician who understands these gaps from the inside, you can find a Black nephrologist or kidney specialist in our directory. For the bigger picture on kidney risk and the APOL1 gene, read our guide to kidney disease in Black adults.